Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-021-04309-y
Abstract: Neuroblastoma (NB) is the most common extracranial solid tumor in children. Interference with the polyamine biosynthesis pathway by inhibition of MYCN-activated ornithine decarboxylase (ODC) is a validated approach. The ODC inhibitor α-difluoromethylornithine (DFMO, or Eflornithine)… read more here.
Keywords: probenecid; activity dfmo; dfmo; antitumor activity ... See more keywords
ETMR-18. TARGETING Lin28 IN ETMR WITH ODC1 INHIBITOR DFMO
Sign Up to like & getrecommendations! Published in 2020 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaa222.221
Abstract: Abstract Embryonal tumor with multilayered rosettes (ETMR), is an aggressive brain tumor primarily occurring in young patients ( read more here.
Keywords: etmr; odc1 inhibitor; dfmo; lin28 ... See more keywords
EXTH-96. CT-2A sublines with divergent immune phenotypes: therapeutic implications for polyamine blockade
Sign Up to like & getrecommendations! Published in 2025 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaf201.1429
Abstract: Polyamines are small molecules that play a critical role in tumor progression and in the regulation of immune responses within the tumor microenvironment. Elevated levels of polyamines in cerebrospinal fluid and tumor tissue have been… read more here.
Keywords: phenotypes therapeutic; divergent immune; sublines divergent; exth sublines ... See more keywords
DFMO and 5-azacytidine increase M1 macrophages in the tumor microenvironment of murine ovarian cancer.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer research"
DOI: 10.1158/0008-5472.can-18-4018
Abstract: Although ovarian cancer has a low incidence rate, it remains the most deadly gynecologic malignancy. Previous work has demonstrated that the DNMTi 5-Azacytidine (AZA) activates type I interferon signaling to increase IFNγ+ T cells and… read more here.
Keywords: ovarian cancer; tumor microenvironment; cancer; dfmo ... See more keywords
Abstract 6725: Targeting urea cycle dysfunction to prevent and treat osteosarcoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-6725
Abstract: Introduction: Osteosarcoma (OS) is the most common primary malignant bone tumor in adolescents and young adults. Intensive multimodal treatment cures almost 75% of patients who present with localized disease; however, only 25% of patients who… read more here.
Keywords: proliferation; growth; urea cycle; dfmo ... See more keywords
Abstract 5122: Modulating anti-GD2 immunotherapy via dual DFMO and TGF-β inhibition in neuroblastoma
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-5122
Abstract: Neuroblastoma (NB) is an often-lethal childhood solid tumor. Anti-GD2 immunotherapy improves survival but not all responses are durable. Transforming growth factor-beta (TGFβ) has been implicated in solid tumor immunoresistance. High-risk NBs harbor activated MYC or… read more here.
Keywords: anti gd2; tgf; tumor; galunisertib ... See more keywords
Abstract 2623: Targeted therapy with DFMO and immunotherapy equalizes survival in MYCN-amplified neuroblastoma: insights from genomic and network analyses
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-2623
Abstract: This study evaluates the efficacy of difluromethylornithine (DFMO) combined with immunotherapy for its potential as a targeted therapy to mitigate outcome differences associated with MYCN amplification in neuroblastoma (NB). A clinical trial was conducted involving… read more here.
Keywords: immunotherapy; analysis; network analyses; targeted therapy ... See more keywords
Evaluating Difluoromethylornithine Safety and Efficacy for Non-Melanoma Skin Cancer Chemoprevention: A Systematic Review
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Cutaneous Medicine and Surgery"
DOI: 10.1177/12034754241302818
Abstract: Introduction: Recent FDA approval of difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase for the prevention of neuroblastoma in children, has renewed interest in this medication for the prevention of other cancers including keratinocyte carcinomas (KCs).… read more here.
Keywords: cancer chemoprevention; melanoma skin; efficacy; non melanoma ... See more keywords
Difluoromethylornithine Induces Apoptosis through Regulation of AP-1 Signaling via JNK Phosphorylation in Epithelial Ovarian Cancer
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms221910255
Abstract: Difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), has promising activity against various cancers and a tolerable safety profile for long-term use as a chemopreventive agent. However, the anti-tumor effects of DFMO in ovarian… read more here.
Keywords: epithelial ovarian; jnk; treatment; dfmo ... See more keywords